Safety and Efficacy Study of 225Ac-DOTA-IBA in the Treatment of Bone Metastases

20260 citationsJournal Article

Authors

Hongyi Liu · Southwest Medical University

Xiaoyan Shang · Southwest Medical University

Yueqi Zhao · Southwest Medical University

Ke Cheng · Southwest Medical University

Xinyue Guo · Southwest Medical University

Naiguo Xing · Southwest Medical University

Wei Wang ·

Abstract

This study indicated that 225Ac-DOTA-IBA was a promising and well-tolerated therapeutic for bone metastases, demonstrating acceptable toxicity and notable efficacy, including 177Lu-DOTA-IBA-refractory cases. Subgroup analyses indicated that patients with bone-only metastases derived particular clinical benefit.

Topics & Keywords

Radiopharmaceutical Chemistry and Applications Prostate Cancer Treatment and Research Management of metastatic bone disease

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Nuclear Medicine

Volume 51, Issue 4, pp. 325-331

DOI: 10.1097/rlu.0000000000006333

Field-Weighted Citation Impact: 0.00